SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is currently trending as investors focus on the potential for a gamma squeeze driven by high call option interest and imminent data readouts from the AACR conference. The community remains deeply divided, with bulls highlighting the long survival tails in clinical trials as evidence of therapeutic success, while bears express skepticism regarding trial design consistency and regulatory approval hurdles.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is experiencing heightened investor activity driven by the U.S. government's recent mandates for space-based nuclear initiatives and ongoing optimism regarding micro-reactors to power AI data centers. While the community is actively debating the company's long-term commercialization timeline and regulatory hurdles, social sentiment remains a mix of intense retail speculation on short-term volatility and institutional interest in the broader nuclear energy thematic.

Daddy Darth Sidious

The community is actively discussing a potential market rotation from related tokens into SIDIOUS, with participants debating whether it represents a genuine opportunity or a speculative pump-and-dump scheme. Traders are focusing on social momentum and strategic entry points, aiming to capitalize on expected volatility leading into the weekend.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is seeing intense investor focus as the company gears up for earnings, with community discussions heavily centered on the potential for a short squeeze given the stock's elevated short interest and upcoming volatility. Traders are closely monitoring the company's recent strategic acquisitions and their ability to transition into commercial production, while broader sector synergy with AI-driven quantum hardware remains a key catalyst driving bullish sentiment.

Bubble Protocol (BPL) is the utility token powering the BubbleSwap ecosystem on Shido Network.  BPL is designed to reduce trading fees, reward long-term holders through staking, and provide access to ecosystem opportunities such as BubblePad airdrops.  With a fixed supply of 20M tokens and a buyback &amp; burn mechanism tied to protocol activity, BPL is built around real usage and growth, not speculation.

Bubble Protocol

Bubble Protocol is gaining momentum as community members highlight its ecosystem and the Bubbleswap platform, fueling speculation about a new cycle of growth.

Daddy Darth Vader

The community is actively engaged in a rivalry known as the 'Daddy Wars' between $DARTH, $MAULCOIN, and the newly launched $SIDIOUS. Investors are debating the long-term viability of these meme tokens, with discussions heavily focused on liquidity management, the transparency of project developers, and strategic rotation between the competing assets.

Based is a financial superapp built on Hyperliquid that lets users trade crypto, equities, and commodities from a single interface, fund accounts directly from bank accounts or credit cards, and spend balances at over 100 million merchants worldwide using a Visa Platinum card that converts at the point of sale with no separate off-ramp required. The platform operates across web, iOS, Android, and desktop with one account, and includes features like curated Launchpools for early project access and AI-native wallets for autonomous trading and risk monitoring.

Based Token

BASED is currently a focal point for market participants debating whether it represents a sustainable crypto super-app with genuine utility or a volatile, manipulated asset prone to aggressive short-term price swings. Investors are actively discussing the token's high leverage and volume-to-market-cap ratio, with many divided between those anticipating a major short squeeze and those warning of potential liquidity traps.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is seeing increased investor attention as the community anticipates critical clinical data readouts and potential regulatory milestones. Shareholders are actively debating the company's valuation relative to recent industry acquisitions, focusing on the upcoming prostate cancer data as a primary catalyst for a long-awaited revaluation.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

BNB is experiencing heightened market activity as traders closely monitor technical resistance levels and institutional movements, including recent reclassifications in reserve holdings. The community remains deeply divided, with some investors focused on potential utility and deflationary mechanics while others voice skepticism regarding regulatory scrutiny and historical market sentiment.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is facing significant volatility and intense investor debate as the stock faces downward pressure despite delivering strong earnings and raising guidance. The community is actively discussing whether the recent sharp decline is a temporary overreaction to marketing initiatives and broad market sentiment or a signal of a deeper, long-term valuation correction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS $GILD $XBI 80% Orr in TP53 AML  
 
$ABBV owns Ven Rhhby BMY Aza Jazz  Otsuka  
Many Big Pharma&#39;s understand the Value of 80% + + Response Rates for AML -MR Tp53/Ras/ Asxl1 who have NO Options.

OnTheBalance

5,500% ROI this quarter

David Maibaum

Tony M

Jeremy Dworkin

$SLS Does everyone See where it says - NOT EFFECTIVE FOR TP53 ?  
 
SLS009 is the only Effective Agent for TP53 and AML-Mr . 
$GILD Paid $4.9B for $FTSV Magrolimab based on its PH1B Data showing Efficacy in this Deadly AML Mutation. 
 
SLS009 P2B Data was Better / and Dr. Amrein is About to Present More Data Showing its Even Better than the Previously Published Data. 
 
Just the Secondary ASSET is NOW - Right Now worth $27 Per Share  
And - AND We have Phase Registrational Results Incoming any day now and for Sure Not Much Longer - Gps Immunotherapy will Revolutionize AML Remission Maintenance Treatment  
- Float is Thinning - No REAL HOLDLERS are Letting ANY GO Before the P3 Results Launch the Share Price. 
---

StockTwits Web

Gilead Sciences, Inc.

Forty Seven, Inc.

$SLS Simple Fact -- SLS009 / PH2B 57% ORR for Tp53 end stage is worth $27 Per Share Right Now.

SPDR S&P Biotech ETF

Abbvie Inc

 owns Ven Rhhby BMY Aza Jazz  Otsuka  
Many Big Pharma's understand the Value of 80% + + Response Rates for AML -MR Tp53/Ras/ Asxl1 who have NO Options.